Try our beta test site

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo (EXPEDITION 3)

This study has been terminated.
(Solanezumab did not meet the study's primary endpoint.)
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01900665
First received: July 12, 2013
Last updated: March 7, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2017
  Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: December 21, 2016